Date:	_2021-5-25
Your Name:Ya	nfang Liang
ManuscriptTitle:	Beta-1 syntrophin (SNTB1) regulates colorectal cancer progression and stemness
via regulation of th	ne Wnt/β-catenin signaling pathway
Manuscript number	er (if known:

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current

manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	: 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses	None	

4	Consulting force	d None	
4	Consulting fees	√_None	
5	Payment or honoraria for		
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√_None	
	testimony		
7	Support for attending	√None	
	meetings and/or travel		
	Detects plants I be a l	J. Maria	
8	Patents planned, issued	√None	
	or pending		
9	Participation on a Data	√_None	
	Safety Monitoring Board		
	or Advisory Board		
10	Leadership or fiduciary	√_None	
	role in other board,		
	society, committee or		
	advocacy group, paid or		
	unpaid		
11	Stock or stock options	√None	
12	Receipt of equipment,	√None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
		· · · · · · · · · · · · · · · · · · ·	
Ple	ease summarize the abo	ve conflict of interest in the following box:	
_			
	I have no conflict of interest.		
'			
-			
Ple	ease place an "X" next to	the following statement to indicate your agreement:	

Date:	2021-5-25
Your Name:	Bin Wang
Manuscript Title	e: Beta-1 syntrophin (SNTB1) regulates colorectal cancer progression and stemness
via regulation	of the Wnt/β-catenin signaling pathway
Manuscript num	nber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current

manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses	None	

1	Consulting fees	√ None	
4	Consulting fees	√_None	
_	Day was and an house of a	./ Name	
5	Payment or honoraria for	√None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events	, Niere	
6	Payment for expert	√None	
	testimony		
_	0 16 11 11		
7	Support for attending	√None	
	meetings and/or travel		
8	Patents planned, issued	√None	
-	or pending		
	1 3		
9	Participation on a Data	√None	
	Safety Monitoring Board		
	or Advisory Board		
10	Leadership or fiduciary	√None	
.	role in other board,	<u> </u>	
	society, committee or		
	advocacy group, paid or		
	unpaid		
11	Stock or stock options	√ None	
12	Receipt of equipment,	√ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	√ None	
	financial interests		
Ple	ease summarize the abo	ve conflict of interest i	n the following box:
_			
	I have no conflict of interest.		
	or microst.		
Б.	///		
Ple	ase place an "X" next to	the following stateme	nt to indicate your agreement:

Date:	2021-5-25			
Your Name:_	_Shasha Chen_			
Manuscript T	itle: <u>Beta–1 syntro</u>	ohin (SNTB1) regulates c	colorectal cancer progression	n and stemness
via regulation	on of the Wnt/β-c	atenin signaling pathwa	У	
Manuscript n	umber (if known):			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current

manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses	None	

4	Conquiting force	A None	
4	Consulting fees	None	
5	Payment or honoraria for		
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	√None	
	meetings and/or travel		
	Data da ala sanda da anti-	L Nicos	
8	Patents planned, issued	None	
	or pending		
9	Participation on a Data	None	
	Safety Monitoring Board		
	or Advisory Board		
10	Leadership or fiduciary	None	
	role in other board,		
	society, committee or		
	advocacy group, paid or		
	unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,		
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
		•	
Ple	ease summarize the abo	ve conflict of interest in the following box:	
	I have no conflict of interest.		
'			
_			
Ple	ase place an "X" next to	the following statement to indicate your agreement:	

Date:2	021-5-25
Your Name: Ziyu	Ye
Manuscript Title: Be	ta-1 syntrophin (SNTB1) regulates colorectal cancer progression and stemnes
via regulation of t	he Wnt/β–catenin signaling pathway
Manuscript number	(if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current

manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	VNone	
3	Royalties or licenses	None	

4	Consulting fees	√None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert		
	testimony		
7	Support for attending meetings and/or travel	√None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	
	ease summarize the about	ve conflict of interest in	the following box:
Ple	Please place an "X" next to the following statement to indicate your agreement:		

Date:	2021-5-25
Your Name:X	Kingxing Chai
Manuscript Title:	Beta-1 syntrophin (SNTB1) regulates colorectal cancer progression and stemness
via regulation of	of the Wnt/β-catenin signaling pathway
Manuscript num	ber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current

manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	√None		
_				
5	Payment or honoraria for	None		
	lectures, presentations, speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	√None		
	testimony			
_				
7	Support for attending	None		
	meetings and/or travel			
8	Patents planned, issued	√None		
	or pending			
9	Participation on a Data	√None		
	Safety Monitoring Board or Advisory Board			
10	Leadership or fiduciary	√ None		
10	role in other board,			
	society, committee or			
	advocacy group, paid or			
	unpaid			
11	Stock or stock options	√None		
12	Receipt of equipment,	√None		
12	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non- financial interests	√None		
Ple	ease summarize the abo	ve conflict of interest in t	the following box:	
	I have no conflict of interest.			
Ple	Please place an "X" next to the following statement to indicate your agreement:			

Date:	2021-5-25	
Your Name:_	Ronggang Li	
Manuscript T	itle: <u>Beta–1 syntrophin (S</u>	SNTB1) regulates colorectal cancer progression and stemness
via regulatio	on of the Wnt/β–catenir	signaling pathway
Manuscript n	number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u>

manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	VNone	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	√None	
6	Payment for expert testimony	√None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	√_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√None	
11	Stock or stock options	√None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	√None	
13	Other financial or non- financial interests	√None	
	ease summarize the about	ve conflict of interest in	the following box:

Please place an "X" next to the following statement to indicate your agreement:

Date:	2021-5-25
Your Name:	_Xiaoping Li
Manuscript Titl	le: Beta-1 syntrophin (SNTB1) regulates colorectal cancer progression and stemnes
via regulation	n of the Wnt/β-catenin signaling pathway
Manuscript nui	mber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current

manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Canadhin - f	A Name			
4	Consulting fees	√_None			
5	Payment or honoraria for	√_None			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	√None			
	testimony				
7	Support for attending	√ None			
	meetings and/or travel				
	3				
8	Patents planned, issued	√None			
	or pending				
9	Participation on a Data	√None			
	Safety Monitoring Board				
	or Advisory Board				
10	Leadership or fiduciary	√None			
	role in other board,				
	society, committee or				
	advocacy group, paid or				
	unpaid				
11	Stock or stock options	√None			
12	Receipt of equipment,	√ None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	√ None			
	financial interests				
Ple	ease summarize the abo	ve conflict of interest in t	he following box:		
	Please summarize the above conflict of interest in the following box:				
	I have no conflict of interest.				
Thave no conflict of interest.					
DIA	assa placa an "V" novi ta	the following statement	to indicate your agreement:		
716	ase Diace at A HeXLIC	i ine ionowina statement	to morcate vour aureement.		

Date:2021-5-25
Your Name:Gang Kong
Manuscript Title: Beta-1 syntrophin (SNTB1) regulates colorectal cancer progression and stemnes
via regulation of the Wnt/β-catenin signaling pathway
Manuscriptnumber(if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interest below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit hird parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, is preferable that you do so.

The following questions apply to the author's relationships/activities/interests they relate to the <u>current</u> manuscriptonly.

The author's relationships/activities/interests ould be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	Ti	Name all entities with whom you have this relationship or indicate none (add rows as needed) me frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work
1	All support for the	_√None	
	present manuscript (e.g.,		
	funding, provision of		
	study materials, medical		
	writing, article processing		
	charges, etc.)		
	No time limit for this		
	item.		
		Time frame: past	36 months
2	Grants or contracts from	√None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	√None	

4	O an audition of the	./ Niere	
4 C	Consulting fees	√None	
_			
5	Payment or honoraria for	√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√None	
	testimony		
_			
7	Support for attending	√None	
	meetings and/or travel		
8	Patents planned, issued	√None	
	or pending		
	, ,		
9	Participation on a Data	√None	
	Safety Monitoring Board		
	or Advisory Board		
10	Leadership or fiduciary	√None	
	role in other board,		
	society, committee or		
	advocacy group, paid or		
	unpaid		
11	Stock or stock options	√None	
12	Receipt of equipment,	√None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	√None	
	financial interests		
Ple	ease summarize the abo	ve conflict of interest in	the following box:
_			
	I have no conflict of interest.		
Ple	ease place an "X" next to	the following statemen	t to indicate your agreement:

Date:	_2021-5-25
Your Name:Ya	anyun Li
Manuscript Title:	Beta–1 syntrophin (SNTB1) regulates colorectal cancer progression and stemness
via regulation o	f the Wnt/β–catenin signaling pathway
Manuscript numb	er (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current

manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

1	Conquiting for-	al None			
4	Consulting fees	√_None			
5	Payment or honoraria for	√None			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	None			
	testimony				
7	Support for attending	√None			
	meetings and/or travel				
8	Patents planned, issued	√None			
0		vivone			
	or pending				
_	Double in etien en e Dete	√ None			
9	Participation on a Data	√None			
	Safety Monitoring Board				
40	or Advisory Board				
10	Leadership or fiduciary	√None			
	role in other board,				
	society, committee or				
	advocacy group, paid or				
4.4	unpaid				
11	Stock or stock options	√_None			
12	Receipt of equipment,	None			
	materials, drugs, medical				
	writing, gifts or other				
10	services				
13	Other financial or non-	√_None			
	financial interests				
Г.					
Ple	ease summarize the abo	ve conflict of interest in	the following box:		
	I have no conflict of interest.				
PΙ	ease place an "X" next to	Please place an "X" next to the following statement to indicate your agreement:			

Date:	2021-5-25
Your Name:>	Kueying Zhang
Manuscript Title	: Beta-1 syntrophin (SNTB1) regulates colorectal cancer progression and stemness
via regulation	of the Wnt/β-catenin signaling pathway
Manuscript num	ber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u>

manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	√None			
5	Payment or honoraria for	√ None			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
6	educational events	A None			
6	Payment for expert testimony	None			
	Codimony				
7	Support for attending	√None			
	meetings and/or travel				
8	Patents planned, issued	None			
	or pending				
9	Participation on a Data	√ None			
5	Safety Monitoring Board				
	or Advisory Board				
10	Leadership or fiduciary	√None			
	role in other board,				
	society, committee or advocacy group, paid or				
	unpaid				
11	Stock or stock options	√None			
	·				
12	Receipt of equipment,	None			
	materials, drugs, medical writing, gifts or other				
	services				
13	Other financial or non-	√None			
	financial interests				
Ple	ease summarize the abo	ve conflict of interest in	the following box:		
	Please summarize the above conflict of interest in the following box:				
	I have no conflict of interest.				
DI -	one place on "V" mand to	و ماه ماه ماه ماه ماه ماه ماه ماه ماه	ak ka in dia da waxa ana ana ana ana		
PIE	Please place an "X" next to the following statement to indicate your agreement:				

Date:	_2021-5-25
Your Name:Zł	nengping Che
Manuscript Title:	Beta–1 syntrophin (SNTB1) regulates colorectal cancer progression and stemness
via regulation o	f the Wnt/β–catenin signaling pathway
Manuscript numb	er (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u>

manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting force	d None		
4	Consulting fees			
5	Payment or honoraria for			
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	√None		
	testimony			
7	Support for attending	√ None		
-	meetings and/or travel			
8	Patents planned, issued	√None		
	or pending			
9	Participation on a Data	√ None		
	Safety Monitoring Board			
	or Advisory Board			
10	Leadership or fiduciary	√None		
.	role in other board,			
	society, committee or			
	advocacy group, paid or			
	unpaid			
11	Stock or stock options	√_ None		
' '	Stock of Stock options			
10				
12	Receipt of equipment,	√_None		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	√_None		
	financial interests			
Ple	ease summarize the abo	ve conflict of interest in the following box:		
_				
	I have no conflict of interest.			
-				
PI۵	ase place an "X" next to	the following statement to indicate your agreement:		

Date:	2021-5-25	
Your Name:Q	Ni Xie	
Manuscript Title:	Beta-1 syntrophin (SNTB1) regulates colorectal cancer progression and ste	mness
via regulation o	of the Wnt/β-catenin signaling pathway	
Manuscript numb	per (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u>

manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses	None	

4	Consulting fees	None			
	-				
5	Payment or honoraria for	√None			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	√None			
	testimony				
7	O and the second second				
7	Support for attending	√None			
	meetings and/or travel				
		,			
8	Patents planned, issued	√None			
	or pending				
_					
9	Participation on a Data	√None			
	Safety Monitoring Board				
40	or Advisory Board				
10	Leadership or fiduciary role in other board,	√None			
	society, committee or advocacy group, paid or				
	unpaid				
11	Stock or stock options	√ None			
• •	Clock of Clock options				
12	Receipt of equipment,	√None			
-	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	√None			
	financial interests				
Г.					
Ple	Please summarize the above conflict of interest in the following box:				
	I have no conflict of interest.				
_					
Ple	ase place an "X" next to	the following statemer	Please place an "X" next to the following statement to indicate your agreement:		

Date:	2021-5-25
Your Name:	_Jiachun Lian
Manuscript Tit	le: Beta-1 syntrophin (SNTB1) regulates colorectal cancer progression and stemness
via regulation	n of the Wnt/β-catenin signaling pathway
Manuscript nu	mber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current

manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	√None		
5	Payment or honoraria for	√_None		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
6	educational events	a/ None		
6	Payment for expert testimony	None		
	testimony			
7	Support for attending	√ None		
′	meetings and/or travel			
	meetings and/or traver			
	Data da			
8	Patents planned, issued	None		
	or pending			
9	Participation on a Data	√ None		
9	Safety Monitoring Board	vivorie		
	or Advisory Board			
10	Leadership or fiduciary	√ None		
10	role in other board,			
	society, committee or			
	advocacy group, paid or			
	unpaid			
11	Stock or stock options	√None		
12	Receipt of equipment,	√None		
	materials, drugs, medical			
	writing, gifts or other			
10	services Other financial or non-	√ None		
13	financial interests	v_none		
	ilitariciai litterests			
	Please summarize the above conflict of interest in the following box: I have no conflict of interest.			
Ple	Please place an "X" next to the following statement to indicate your agreement:			

Date:	2021-5-25		
Your Name:	Bihua Lin		
Manuscript T	Fitle: <u>Beta–1 syntrophin</u>	(SNTB1) regulates colorectal cancer progression and st	temness
via regulati	on of the Wnt/β–cater	nin signaling pathway	
Manuscript n	number (if known):		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u>

manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	VNone	

4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	VNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	√None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	
	ease summarize the abo		the following box:

Please place an "X" next to the following statement to indicate your agreement:

Date:	2021-5-25
Your Name:>	Kin Zhang
Manuscript Title	: Beta–1 syntrophin (SNTB1) regulates colorectal cancer progression and stemness
via regulation	of the Wnt/β–catenin signaling pathway
Manuscript num	ber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current

manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	O an audition of the	, Nana		
4 Co	Consulting fees	√_None		
_				
5	Payment or honoraria for	√None		
	ectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events	/ Ni		
6	Payment for expert	√None		
	testimony			
_				
7	Support for attending	√None		
	meetings and/or travel			
8	Patents planned, issued	√None		
	or pending			
	, ,			
9	Participation on a Data	√None		
	Safety Monitoring Board			
	or Advisory Board			
10	Leadership or fiduciary	√None		
	role in other board,			
	society, committee or			
	advocacy group, paid or			
	unpaid			
11	Stock or stock options	√None		
12	Receipt of equipment,	√None		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	√None		
	financial interests			
PΙε	ease summarize the abo	ve conflict of interest in t	he following box:	
	I have no conflict of interest.			
PΙε	ease place an "X" next to	the following statement	to indicate your agreement:	

Date:	2021-5-25
Your Name:	Kueqin Huang
Manuscript Title	: Beta-1 syntrophin (SNTB1) regulates colorectal cancer progression and stemness
via regulation	of the Wnt/β-catenin signaling pathway
Manuscript num	iber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u>

manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	√None		
5	Payment or honoraria for	√None		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	√ None		
	testimony			
	tooty			
7	Support for attending	√ None		
'	meetings and/or travel	vNone		
	meetings and/or travel			
8	Patents planned, issued	√None		
	or pending			
	o. ponanig			
9	Participation on a Data	None		
ا "	Safety Monitoring Board			
	or Advisory Board			
10	<u> </u>	l Ni		
10	Leadership or fiduciary	√None		
	role in other board,			
	society, committee or			
	advocacy group, paid or			
	unpaid			
11	Stock or stock options	√None		
12	Receipt of equipment, materials, drugs, medical	√None		
	writing, gifts or other			
	services			
13	Other financial or non-	√None		
	financial interests			
		-		
Ple	ease summarize the abo	e conflict of interest in the follow	wing box:	
	Please summarize the above conflict of interest in the following box:			
	I have no conflict of interest			
I have no conflict of interest.				
- וח	soo place on "Y" north-	the following statement to in all a	ata vaur agraemant:	
716	ase place all A liext to	the following statement to indic	ate your agreement.	

Date:	2021-5-25
Your Name:V	Veijuan Huang
Manuscript Title	: Beta–1 syntrophin (SNTB1) regulates colorectal cancer progression and stemness
via regulation	of the Wnt/β–catenin signaling pathway
Manuscript num	ber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current

manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	√None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√ None	
	testimony		
7	Support for attending	√ None	
'	meetings and/or travel		
	meetings and/or traver		
8	Patents planned, issued	√None	
	or pending		
	or borrowing		
9	Participation on a Data	√None	
	Safety Monitoring Board		
	or Advisory Board		
10	Leadership or fiduciary	√None	
10	role in other board,	vnone	
	society, committee or		
	advocacy group, paid or		
4.4	unpaid	, Name	
11	Stock or stock options	√None	
12	Receipt of equipment,	√None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	√None	
	financial interests		
Ple	ease summarize the abo	ve conflict of interest in	the following box:
_	I have no conflict of interest.		
L			
D.	where on "V"	the fellowing statemen	mt to indicate very care and
716	ease piace an A next to	o the following stateme	nt to indicate your agreement:

Date:	2021-5-25
Your Name:	_Xianxiu Qiu
Manuscript Tit	le: Beta–1 syntrophin (SNTB1) regulates colorectal cancer progression and stemness
via regulation	n of the Wnt/β-catenin signaling pathway
Manuscript nu	mber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u>

manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	VNone	

4	Consulting fees	√None	
	_		
5	Payment or honoraria for	√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√None	
	testimony		
7	Support for attending	√None	
	meetings and/or travel		
8	Patents planned, issued	√ None	
Ū	or pending		
	от ретинд		
9	Participation on a Data	√ None	
	Safety Monitoring Board		
	or Advisory Board		
10	Leadership or fiduciary	√ None	
	role in other board,		
	society, committee or		
	advocacy group, paid or		
	unpaid		
11	Stock or stock options	√None	
12	Receipt of equipment,	√None	
	materials, drugs, medical		
	writing, gifts or other		
40	services		
13	Other financial or non-	√_None	
	financial interests		
יום	acco cummariza tha aba	vo conflict of interest in	the following boy:
F16	ease summarize the abo	ve commet of interest if	i the following box.
Г	I have no conflict of interest.		
	Thave no conflict of interest.		
D.		Alexa Callianado (1911)	A A - Co-Pi- A - Co-Pi
Ple	ase piace an "X" next to	the following statemer	nt to indicate your agreement:

Date:	2021-5-25	
Your Name	:JinchengZeng	
Manuscript	:Title: <u>Beta–1 syntrop</u>	hin (SNTB1) regulates colorectal cancer progression and stemness
via regulat	ion of the Wnt/β–ca	atenin signaling pathway
Manuscript	number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	Ti	Name all entities with whom you have this relationship or indicate none (add rows as needed) me frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the	The frame. Cined the finitia	Planning of the Work
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Guangdong Basic and Applied Basic Research Foundation	This payments are made to my institution
		Dongguan Social Science and Technology Development Project	This payments are made to my institution
		Shenzhen Basic Research Program	This payments are made to my institution
		the Key Cultivation Project of Guangdong Medical University	This payments are made to my institution

Time frame: past 36 months			
2	Grants or contracts from	√None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√None	
5	Payment or honoraria for	√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events		
6	Payment for expert	√None	
	testimony		
_	0 16 11 11		
7	Support for attending meetings and/or travel	√None	
8	Patents planned, issued	√None	
	or pending		
9	Participation on a Data	√None	
	Safety Monitoring Board		
	or Advisory Board		
10	Leadership or fiduciary	√None	
	role in other board,		
	society, committee or		
	advocacy group, paid or		
	unpaid		
11	Stock or stock options	√None	
10	Daniel of an invest	/ N1	
12	Receipt of equipment,	None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	√None	
	financial interests		

Please summarize the above conflict of interest in the following box:

The author reports funding form Guangdong Basic and Applied Basic Research Foundation; Dongguan Social Science and Technology Development Project; Shenzhen Basic Research Program, and the Key Cultivation Project of Guangdong Medical University.

Please place an "X" next to the following statement to indicate your agreement: